

# Minutes of the NMEP-PVAC Project Bi-weekly meeting

## A. Meeting Details

- **Date:** 16<sup>th</sup> October 2025.
- **Duration:** 2:00 pm – 2:38 pm.
- **Venue:** Virtual via Microsoft Teams
- **Meeting Participants:** Six (6).

### Meeting participants

S/N	Name	Organization	Designation
1	Dr Philip Okoko	IMPACT	Project Manager
2	Dorothy Ezeokpube	NMEP	Chief Accountant
3	Uchenna Aja Apuru-Aja	HSCCL	Programme Manager
4	Bolaji Akala	IHC	Team Lead
5	Mubarak Ahmed	IHC	Programmes Lead
6	Tosin Adeniyi	IHC	Programmes Associate

## B. Project Updates

- **Stakeholder Validation and Co-Creation Workshop**
  - Successfully held last week with 116 participants in attendance.
  - All consultants across workstreams (ACT, LLIN, RDT, Vaccines, and Clinical Research) presented their assessment findings.
  - Stakeholders expressed satisfaction with the findings and actively contributed by providing feedback on the findings and participating in the technical working group sessions covering Manufacturing, Regulatory, and Market themes.
  - Consultants have been tasked with the task of revising their reports with the aim to integrate stakeholders' inputs and submit finalized versions (PowerPoint and MS word) by October 24, 2025.
- **Consultant Deliverables and Technical Assistance**
  - Consultants are currently updating reports based on workshop feedback.
  - PVAC plans to hold an alignment meeting with consultants to define the scope and expectations of technical support for selected manufacturers.
  - The consultants are expected to submit manufacturer-specific capacity development plans on or before October 24, 2025.
  - Non-Disclosure Agreements (NDAs) were signed with PMG-MAN by Empower Swiss and Infinity Health to safeguard of the data shared.
  - The overall strategic roadmap is targeted for completion by the end of October 2025.
- **White Paper Development**
  - The White Paper remains pending as priority recommendations from each workstream are being harmonized.
  - Draft expected by the end of October 2025, once all consultant reports are finalized.
- **Work Plan and Activity Tracking**
  - Activities marked in yellow on the tracker (e.g., monthly reports, M&E updates) are ongoing until project close-out.
  - Completed activities include stakeholder engagements, MOU signings, and dissemination of priority recommendations.
  - Pending items (e.g., technical assistance reports, list of manufacturers, procurement committee setup) on the workplan depends on the finalization of the various project reports.

- **Pooled Procurement Workstream**
  - Consultant is finalizing the costed capacity development plan.
  - Consultant is yet to commence the process of establishing state-level pooled procurement committees.

### C. Discussion Points

- **Manufacturer Selection Criteria**
  - PVAC confirmed that a preliminary list of selected manufacturers for technical support has been received but is currently undergoing final validation.
  - Criteria for selection include registration status, raw material access, financial systems, production capacity, and readiness for scale-up.
- **Timeline for Technical Support**
  - The technical support phase was initially planned for September–December 2025 (4 months).
  - Due to workshop rescheduling and ongoing report reviews, the exact start date will be confirmed after PVAC’s meeting with consultants next week.
  - Activities will cover technology transfer, quality assurance strengthening, and operational efficiency improvements.
- **Project Continuity and NMEP’s 2026 Work Plan**
  - Dr. Philip emphasized the need for a realistic and revised timeline in case there is a need for extension so that it can be captured in the NMEP 2026 workplan.
  - This revised timeline will inform the 2026 work plan and ensure proper documentation for World Bank review and funding alignment.
- **Pooled Procurement Committees**
  - The team clarified that the capacity development plan is state-specific and was built based on the identified gaps within Drug Management Agencies (DMAs) and Departments of Pharmaceutical Services (DPS) that were assessed.
  - The Pooled Procurement Committees (PPCs) will leverage existing state structures for sustainability and will focus on public health commodity procurement.
  - In states where PPCs exist but are non-functional, PVAC will support their reactivation and optimization.
  - Membership of the committee will include malaria project -specific representatives to improve commodity forecasting and supply management.

### D. Next Steps

1. **Consultant Deliverables**
  - All consultants to submit finalized reports and updated recommendations by October 24, 2025.
  - PVAC to consolidate inputs into the Strategic Roadmap and White Paper by end of October.
2. **Alignment & Technical Support Planning**
  - PVAC to convene a consultant alignment meeting next week to define scope, expectations, and timelines for manufacturers’ technical assistance.
  - Finalize the list of manufacturers that were selected for capacity-building support.
3. **Technical Assistance Implementation**
  - Initiate technical support phase immediately after the PVAC-consultants’ alignment meeting.

- Duration and timeline of the capacity building support to be finalized post-NMEP's discussions with the consultants, with activities projected to run through December 2025 (and potentially into early 2026).
4. **Pooled Procurement Workstream**
    - Finalize costed capacity development plan.
    - Begin establishment or reactivation of state-level pooled procurement committees, ensuring inclusion of malaria program representatives.
  5. **Project Planning**
    - PVAC to revise and share updated activity timelines reflecting the adjusted deliverables and 2026 transition needs (if required).
    - Include dissemination and final reporting activities in revised work plan.
  6. **Documentation & Reporting**
    - Draft White Paper to be completed and shared with the team by the end of October 2025 for review